Search Result

Results for "

RNA Recognition Motif

" in MedChemExpress (MCE) Product Catalog:

By Targets:	DNA/RNA Synthesis (3)
By Research Areas:	Cancer (3)

Inhibitors & Agonists

Peptides

Antibodies

Targets Recommended: MicroRNA mRNA RNA MTase Small Interfering RNA (siRNA) CXCR DNA/RNA Synthesis Aminoacyl-tRNA Synthetase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P5960

PTBP1-RNA-binding inhibitor P6 TFA PTBP1 α3-helix derived peptide P6 TFA	DNA/RNA Synthesis	Others
PTBP1-RNA-binding inhibitor P6 (PTBP1 α3-helix derived peptide P6) TFA is a stapled peptide inhibitor of the splicing factor PTBP1, which inhibits alternative splicing events regulated by PTBP1. PTBP1 binds RNA through its RNA recognition motif .

HY-153736

NSC 194308	DNA/RNA Synthesis	Cancer
NSC 194308, a *U2AF2-RNA* complexes enhancer, increases association of the U2AF1-U2AF2-SF1-splice site RNA complex by binding a site between the U2AF2 RNA recognition motifs (RRM1 and RRM2). NSC 194308 inhibits pre-mRNA splicing by stalling spliceosome assembly at the point where U2AF helps recruit U2 snRNP to the branchpoint. NSC 194308 enhances the binding of pre-mRNA to U2AF2, selectively triggering cell death in leukemia cell lines containing spliceosome mutations .

HY-182546

Anticancer agent 312	DNA/RNA Synthesis	Cancer
Anticancer agent 312 is a heterogeneous nuclear ribonucleoprotein A18 (hnRNP A18) inhibitor with an IC₅₀ of 2.9 μM. Anticancer agent 312 binds to the RNA recognition motif of hnRNP A18 and blocks its binding to homologous RNA transcripts. Anticancer agent 312 acts as a protein synthesis inhibitor by blocking hnRNP A18-mediated mRNA translation. Anticancer agent 312 is applicable to research on cancers such as melanoma .

Cat. No.	Product Name	Target	Research Area

HY-P5960

PTBP1-RNA-binding inhibitor P6 TFA PTBP1 α3-helix derived peptide P6 TFA	DNA/RNA Synthesis	Others
PTBP1-RNA-binding inhibitor P6 (PTBP1 α3-helix derived peptide P6) TFA is a stapled peptide inhibitor of the splicing factor PTBP1, which inhibits alternative splicing events regulated by PTBP1. PTBP1 binds RNA through its RNA recognition motif .

HY-P11231

β4-TAT FUS(364-369)-TAT	Peptides	Cancer
β₄-TAT is a kind of β-sheet peptide foldamer. β₄-TAT is composed of two parts: the β4 sequence (derived from the β-sheet fragment of the RRM domain of fused in sarcoma (FUS)) and the TAT sequence (a nuclear localization signal peptide that helps the entire peptide penetrate the nuclear membrane). β₄-TAT influences FUS aggregation by targeting its RNA recognition motifs (RRM). β4-TAT effectively induces FUS aggregation within cells, leading to the death of cancer cells. β₄-TAT can be used for the study of FUS .

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P86293

	RBMY1A1 Antibody (YA5985) RBMY1A1; RBM1; RBM2; YRRM1; YRRM2; RNA-binding Motif protein, Y chromosome, family 1 member A1 ; RNA-binding Motif protein 1; RNA-binding Motif protein 2; Y chromosome RNA Recognition Motif 1; hRBMY;	WB, IHC-P	Human
	RBMY1A1 Antibody (YA5985) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to RBMY1A1.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.